MedPath

Inositol

Generic Name
Inositol
Brand Names
Alertonic
Drug Type
Small Molecule
Chemical Formula
C6H12O6
CAS Number
87-89-8
Unique Ingredient Identifier
4L6452S749
Background

Inositol is a collection of nine different stereoisomers but the name is usually used to describe only the most common type of inositol, myo-inositol. Myo-inositol is the cis-1,2,3,5-trans-4,6-cyclohexanehexol and it is prepared from an aqueous extract of corn kernels by precipitation and hydrolysis of crude phytate. These molecules have structural similarities to glucose and are involved in cellular signaling. It is considered a pseudovitamin as it is a molecule that does not qualify to be an essential vitamin because even though its presence is vital in the body, a deficiency in this molecule does not translate into disease conditions. Inositol can be found as an ingredient of OTC products by Health Canada but all current product whose main ingredient is inositol are discontinued. By the FDA, inositol is considered in the list of specific substances affirmed as generally recognized as safe (GRAS).

Indication

Inositol may be used in food without any limitation. As a drug, inositol is used as a nutrient supplement in special dietary foods and infant formula. As it presents a relevant role in ensuring oocyte fertility, inositol has been studied for its use in the management of polycystic ovaries. Inositol is also being researched for the treatment of diabetes, prevention of metabolic syndrome, aid agent for weight loss, treatment of depression, psychiatric disorder and anxiety disorder and for prevention of cancer.

Non-surgical Periodontal Therapy and Myo-inositol in Polycystic Ovary Syndrome Women Having Chronic Periodontitis

Phase 2
Conditions
Periodontitis
Insulin Resistance
Polycystic Ovary Syndrome
Interventions
Procedure: scaling and root planing , Myo-inositol
First Posted Date
2015-12-17
Last Posted Date
2015-12-17
Lead Sponsor
Postgraduate Institute of Dental Sciences Rohtak
Target Recruit Count
56
Registration Number
NCT02633462

Inositol to Reduce Retinopathy of Prematurity

Phase 3
Terminated
Conditions
Retinopathy of Prematurity (ROP)
Interventions
First Posted Date
2013-10-01
Last Posted Date
2019-03-22
Lead Sponsor
NICHD Neonatal Research Network
Target Recruit Count
638
Registration Number
NCT01954082
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California - Los Angeles, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 16 locations

Inositol in Trichotillomania

Phase 2
Completed
Conditions
Trichotillomania
Hair Pulling
Interventions
Drug: Placebo
First Posted Date
2013-06-11
Last Posted Date
2023-02-23
Lead Sponsor
University of Chicago
Target Recruit Count
38
Registration Number
NCT01875445
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago, Chicago, Illinois, United States

Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial

Early Phase 1
Conditions
Polycystic Ovary Syndrome
Interventions
Drug: Placebo
First Posted Date
2012-04-10
Last Posted Date
2012-04-10
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
70
Registration Number
NCT01574261
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Universitร  cattolica S. Cuore, Rome, Italy

Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone

Not Applicable
Completed
Conditions
Polycystic Ovary Syndrome
Hirsutism
Menstrual Irregularity
Interventions
First Posted Date
2012-03-15
Last Posted Date
2020-07-24
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
50
Registration Number
NCT01555190
Locations
๐Ÿ‡ฎ๐Ÿ‡น

Catholic University of Sacred Heart, Rome, Italy

Inositol and Omega-3 Fatty Acids in Pediatric Mania

Phase 4
Completed
Conditions
Pediatric Bipolar Spectrum Disorders
Interventions
First Posted Date
2011-07-18
Last Posted Date
2020-08-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
69
Registration Number
NCT01396486
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

Phase 1
Terminated
Conditions
Colon Carcinoma
Dysplasia in Crohn Disease
Rectal Carcinoma
Low Grade Dysplasia in Ulcerative Colitis
Interventions
Other: Placebo
First Posted Date
2010-04-27
Last Posted Date
2016-07-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
5
Registration Number
NCT01111292
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mount Sinai Medical Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northwestern University, Chicago, Illinois, United States

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Phase 2
Completed
Conditions
Bronchopulmonary Dysplasia (BPD)
Infant, Newborn
Infant, Low Birth Weight
Infant, Premature
Retinopathy of Prematurity
Infant, Small for Gestational Age
Interventions
First Posted Date
2009-12-11
Last Posted Date
2022-06-14
Lead Sponsor
NICHD Neonatal Research Network
Target Recruit Count
125
Registration Number
NCT01030575
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Iowa, Iowa City, Iowa, United States

๐Ÿ‡บ๐Ÿ‡ธ

Stanford University, Palo Alto, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Emory University, Atlanta, Georgia, United States

and more 14 locations

Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Phase 2
Completed
Conditions
Squamous Lung Dysplasia
Non-small Cell Lung Cancer
Interventions
Other: placebo
First Posted Date
2008-11-02
Last Posted Date
2017-12-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
85
Registration Number
NCT00783705
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

Albuquerque Veterans Administration Medical Center, Albuquerque, New Mexico, United States

and more 1 locations

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

Phase 2
Completed
Conditions
Infant, Low Birth Weight
Retinopathy of Prematurity
Bronchopulmonary Dysplasia (BPD)
Infant, Small for Gestational Age
Infant, Premature
Infant, Newborn
Interventions
Drug: Placebo higher volume
Drug: Placebo lower volume
First Posted Date
2006-07-10
Last Posted Date
2017-06-20
Lead Sponsor
NICHD Neonatal Research Network
Target Recruit Count
74
Registration Number
NCT00349726
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Indiana University, Indianapolis, Indiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Duke University, Durham, North Carolina, United States

and more 8 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath